## Supplementary Table 9. Adverse events of potential cardiovascular disease (CVDs) in patients with comorbidities of dyslipidemia or CVDs at week 96 – safety set

|  |  |  |
| --- | --- | --- |
|  | **TMF 25 mg** | **TDF 300 mg** |
|  | **(N = 666)** | **(N = 336)** |
|  | ***n* (%)** | ***n* (%)** |
| Dyslipidemia or CVDs grade ≥ 3 | 20 (3.0) | 6 (1.8) |
| Creatine phosphokinase increased | 8 (1.2) | 3 (0.9) |
| Hypertriglyceridemia | 3 (0.5) | 0 (0.0) |
| Triglycerides increased | 2 (0.3) | 0 (0.0) |
| Cerebral venous sinus thrombosis | 1 (0.2) | 0 (0.0) |
| Hypoxic ischemic encephalopathy | 1 (0.2) | 0 (0.0) |
| Ventricular extrasystole | 1 (0.2) | 0 (0.0) |
| Cardiomyopathy | 1 (0.2) | 0 (0.0) |
| Markers of myocardial necrosis increased | 1 (0.2) | 0 (0.0) |
| Myocardial ischemia | 1 (0.2) | 0 (0.0) |
| Coronary artery disease | 0 (0.0) | 1 (0.3) |
| Supraventricular tachycardia | 0 (0.0) | 1 (0.3) |
| Cerebral hemorrhage | 0 (0.0) | 1 (0.3) |
| Dyslipidemia or CVDs | 332 (49.8) | 126 (37.5) |
| Dyslipidemia | 192 (28.8) | 41 (12.2) |
| Creatine phosphokinase increased | 64 (9.6) | 34 (10.1) |
| Chest pain | 11 (1.7) | 2 (0.6) |
| Myocardial ischemic electrocardiogram or marker abnormalities | 10 (1.5) | 25 (7.4) |
| Diseases of fat metabolism | 9 (1.4) | 1 (0.3) |
| Sinus bradycardia | 7 (1.1) | 5 (1.5) |
| Sinus arrhythmia | 5 (0.8) | 1 (0.3) |
| Cardiopalmus | 5 (0.8) | 0 (0.0) |
| Ventricular extrasystole | 4 (0.6) | 0 (0.0) |
| Arrhythmia | 3 (0.5) | 1 (0.3) |
| Cerebral ischemia | 3 (0.5) | 0 (0.0) |
| Hepatomegaly | 2 (0.3) | 1 (0.3) |
| Supraventricular extrasystole | 2 (0.3) | 0 (0.0) |
| Loss of adipose tissue | 2 (0.3) | 0 (0.0) |
| Sinus tachycardia | 1 (0.2) | 1 (0.3) |
| Right bundle branch block | 1 (0.2) | 1 (0.3) |
| Orthostatic hypotension | 1 (0.2) | 1 (0.3) |
| Cerebrovascular disorders | 1 (0.2) | 0 (0.0) |
| Breast pain | 1 (0.2) | 0 (0.0) |
| Peripheral edema | 1 (0.2) | 0 (0.0) |
| Wolf-Parkinson-White syndrome | 1 (0.2) | 0 (0.0) |
| ECG PR shortening | 1 (0.2) | 0 (0.0) |
| ECG T wave inverted | 1 (0.2) | 0 (0.0) |
| Bradycardia | 1 (0.2) | 0 (0.0) |
| Myocardial ischemia | 1 (0.2) | 1 (0.3) |
| Lipomyoma | 1 (0.2) | 0 (0.0) |
| Vertebrobasilar artery insufficiency | 1 (0.2) | 0 (0.0) |
| Peripheral artery occlusive disease | 0 (0.0) | 2 (0.6) |
| Constriction of blood vessels in the brain | 0 (0.0) | 1 (0.3) |
| Abnormal directional Doppler blood flow test | 0 (0.0) | 1 (0.3) |
| Ascites | 0 (0.0) | 1 (0.3) |
| Impaired fasting glucose | 0 (0.0) | 1 (0.3) |
| Diastolic blood pressure increased | 0 (0.0) | 1 (0.3) |
| Peripheral swelling | 0 (0.0) | 1 (0.3) |
| Decreased ventricular motor function | 0 (0.0) | 1 (0.3) |
| Cardiomegaly | 0 (0.0) | 1 (0.3) |
| Abnormal computed tomography of the chest | 0 (0.0) | 1 (0.3) |
| Cerebral hemorrhage | 0 (0.0) | 1 (0.3) |